drugset
drugset / Trial / NCT02743598

Liraglutide for HIV-associated Neurocognitive Disorder

NCT02743598 ↗

Phase 4 Terminated 4 enrolled Temple University The Comprehensive NeuroAIDS Center (CNAC) at Temple University · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes.

Timeline

Start
2016-09
Primary completion
2018-06-01
Completion
2018-09

Outcome

Outcome not reported

Stopped (Business): “Lack of funding and time”

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide — —

Indications

HIV infectious disease abdominal obesity-metabolic syndrome obesity disorder type 2 diabetes mellitus